An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-26

Study Completion Date

2017-05-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the safety of extended treatment with Proellex® in women who have successfully completed either study ZPV-201 \[NCT02323646\] or ZPU-203 \[NCT02301897\] and meet eligibility criteria.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200

NCT01739621

Uterine Fibroids

COMPLETED PHASE2

Extension of Study ZPV-200

NCT01631903

Uterine Fibroids

COMPLETED PHASE2

Mifepristone for Treatment of Uterine Fibroids

NCT00712595

Uterine Fibroids

COMPLETED PHASE2/PHASE3

Mifepristone to Treat Uterine Fibroids

NCT01786226

Uterine Fibroids

TERMINATED PHASE2/PHASE3

Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids

NCT00881140

Uterine Fibroid Vaginal Bleeding.

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be for participants who had completed either ZPV-201 or ZPU-203.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Fibroids

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Telapristone Acetate 12 mg

Telapristone acetate 12 milligrams (mg), orally, once daily for two 18-weeks courses (Treatment Courses 1 and 2) separated by an off-drug interval (ODI).

Group Type EXPERIMENTAL

Telapristone acetate

Intervention Type DRUG

Telapristone acetate, orally, once daily for three 18-weeks courses separated by an ODI.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telapristone acetate

Telapristone acetate, orally, once daily for three 18-weeks courses separated by an ODI.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Proellex®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Completed either study ZPV-201 \[NCT02323646\] or ZPU-203 \[NCT02301897\]
* Agreement not to attempt to become pregnant during the trial
* Agreement to use alcohol in moderation and record the daily consumption (note: elevated liver enzymes may result in discontinuation from the study)
* Ability to complete a daily subject diary and study procedures in compliance with the protocol
* Women of child-bearing potential must be willing to use double-barrier contraception during the study and off-drug intervals. Acceptable double-barrier methods are: male condom with spermicide; male condom with diaphragm; diaphragm containing spermicide plus additional intra-vaginal spermicide
* Has a negative pregnancy test at Visit 1
* Subject is available for all treatment and follow-up visits

Exclusion Criteria

* Subject had a significant decrease in bone mineral density while participating in ZPV-201 or ZPU-203 (total hip or spine measurement decreased by 5% or more)
* Subject has undergone hysterectomy and/or bilateral oophorectomy since enrollment in ZPV-201 or ZPU-203
* Subject is pregnant or lactating or is attempting or expecting to become pregnant during the entire study period
* Subjects with abnormally high liver enzymes or liver disease. \[alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding 2 x upper limit of normal (ULN) and total bilirubin exceeding 1.5 x ULN at Visit 1 and confirmed on repeat\].
* Subject has a hemoglobin of \<7.5 grams per deciliter (g/dL) at Visit 1
* Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids, dehydroepiandrosterone (DHEA) or hormonal products for at least 2 weeks prior to Visit 1
* Use of oral contraceptives in the 30 days preceding screening. Use of Depo-Provera® in the preceding 10 months
* Use of Gonadotrophin releasing hormone agonist (GnRHas) (e.g. Lupron Depot) within 3 months prior to screening (Lupron Depot must have a wash-out period of 3 months prior to screening)
* Has an intra-uterine device (IUD) in place
* Current cervical dysplasia classified as Atypical Squamous Cells of Undetermined Significance (ASCUS) associated with high-risk human papilloma virus (HPV)
* Current diagnosis of Low/High Grade Squamous Intraepithelial Lesion (LGSIL or HGSIL), endometrial polyps or hyperplasia
* Observation or history of abnormal endometrial biopsy including the presence of endometrial intraepithelial neoplasia (EIN)
* Recent history (within past 6 months) of alcoholism or drug abuse
* Endometrial stripe ≥18 mm in thickness at Visit 1 (subject may be enrolled with sponsor approval)
* Subject is currently taking cimetidine or spironolactone or has taken them in the last 30 days
* Clinically significant abnormal findings on Visit 1 examination and laboratory assessments or any condition which in the opinion of the investigator would interfere with the subject's ability to comply with the study instructions or endanger the subject if she took part in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

47 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No